Drug Research
eTheRNA advances in-vivo mRNA cancer immunotherapy into first oncology...
eTheRNA immunotherapies, a clinical-stage company developing mRNA based cancer immunotherapies from its unique TriMix platform, announces the start of the first Phase Ib oncology clinical...
Drug Research
Eisai Temporarily Withdraws New Drug Application for Anticancer Agent...
Eisai Co., Ltd. announced today that, in alignment with Chinese regulations, it has temporarily withdrawn its new drug application for anticancer agent eribulin mesylate (Brand...
Drug Research
Sandoz receives approval in Europe for Rixathon® to treat...
Sandoz, a Novartis division, and the pioneer and global leader in biosimilars, announced today that the EC  has approved Rixathon® (biosimilar rituximab*) for use in...
Drug Research
Numerate and Takeda Enter Agreement to Generate Novel Clinical...
Numerate, Inc., a computational drug design company applying artificial intelligence (AI) at cloud scale to transform small molecule drug discovery, announced the formation of a...
Drug Research
Eisai Enters Into Joint Research Agreement With The Broad...
Eisai Co Ltd announced that it has entered into a new joint research agreement with the Broad Institute , a collaborative research institute which includes...
Drug Research
OBI Pharma to develop OBI-3424 (previously TH-3424) as a...
OBI Pharma, Inc., a Taiwan biopharma company announced an agreement with Threshold Pharmaceuticals, Inc. to acquire TH-3424, a first-in-class novel small-molecule prodrug that selectively targets...
Articles
Organs-On-Chips To Revolutionize The Drug Development Industry
The market for organs-on-chips (OOCs), the cell culture chips that imitate the activities, mechanisms and responses of organs, will be worth $284 millionby 2021, according...
Subscribe
- Never miss a story with notifications
- Gain full access to our premium content
- Browse free from any location or device.